3‘-Sialyllactose Outlook: Microbial Fermentation vs. Enzymatic Synthesis for Human Milk Oligosaccharide Supplementation

Introduction: Solving Infant Gut Microbiome Gaps with Human Milk-Identical Oligosaccharide
Infant formula manufacturers, pediatric nutrition developers, and early-life health researchers face a persistent formulation gap: human milk contains numerous human milk oligosaccharides (HMOs) that selectively nourish beneficial gut bacteria (Bifidobacterium longum subsp. infantis), support immune maturation, and inhibit pathogen adhesion. Conventional formula lacks these bioactives. The solution lies in 3‘-sialyllactose (3‘-SL) —a sialylated (acidic) trisaccharide composed of D-glucose, D-galactose, and NANA (N-acetylneuraminic acid, sialic acid). 3‘-SL is an abundant sialylated HMO in human milk (approximately 8-10% of total HMOs in colostrum, 3-5% in mature milk), linked α2,3 to the galactose unit. This report provides a comprehensive forecast of adoption trends, production technology segmentation, application drivers, and regulatory dynamics through 2032.

Global Leading Market Research Publisher QYResearch announces the release of its latest report “3‘-Sialyllactose (3‘-SL) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032” . Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global 3‘-Sialyllactose (3‘-SL) market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for 3‘-Sialyllactose (3‘-SL) was estimated to be worth US31.00millionin2025andisprojectedtoreachUS31.00millionin2025andisprojectedtoreachUS 95.40 million by 2032, growing at a CAGR of 17.1% from 2026 to 2032. In 2025, global production reached approximately 160 metric tons, with an average global market price of around US$ 194 per kilogram. This updated valuation (Q2 2026 data) reflects the sector‘s transition from technical validation toward regulation-led commercialization, driven by China NHC approval (2026) and established EU novel-food authorization.

Product Definition & Key Characteristics
3‘-Sialyllactose (3‘-SL) is a sialylated (acidic) trisaccharide composed of D-glucose, D-galactose and NANA. 3‘-SL is an abundant sialylated HMO in human milk. Key functional benefits include:

• Prebiotic effect: Promotes selective growth of Bifidobacterium longum subsp. infantis (expresses α2,3-sialidase specific to 3‘-SL)
• Anti-adhesive activity: Binds to pathogens (E. coli, Salmonella, Campylobacter, norovirus, rotavirus, H. pylori), preventing intestinal colonization
• Immunomodulation: Modulates immune cell cytokine production (IL-10, IL-12, TNF-α, IFN-γ)
• Neurodevelopment: Sialic acid component supports brain development (ganglioside synthesis, synaptic plasticity, myelination, cognitive function)

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5771888/3–sialyllactose–3–sl

Market Dynamics & Competitive Landscape
The global 3‘-SL market is moving from technical validation toward regulation-led commercialization, and the real competitive battleground is no longer only capacity, but also fermentation manufacturing (titer, yield, purity), purity control (>98% for infant formula grade), cross-border registration (FDA GRAS, EFSA Novel Food, China NHC, FSANZ, Health Canada, Japan FOSHU), and supply reliability (batch-to-batch consistency, contamination control).

Public disclosures show that Kyowa Hakko Bio (Japan) completed an HMO production facility in Thailand and started commercial production in 2022, received FDA no-question letters for 3‘-SL and related HMOs in 2023 (GRAS Notice), and obtained EU novel-food approval for 3‘-SL in 2024, allowing use across multiple food categories in the EU (infant formula, follow-on formula, foods for special medical purposes, food supplements, yogurts, beverages). From an analyst‘s perspective, infant nutrition and premium formulation strategies that seek ingredients closer to human milk are strengthening the value proposition of 3‘-SL, while FDA GRAS records also show that more than one party (Novonesis, Inbiose/dsm-firmenich, DSM, Kyowa Hakko) has pursued compliance pathways, suggesting the category is not locked to a single supplier.

However, high purity requirements (>98% for infant formula, >95% for general food), complex processing (fermentation titer 30-120 g/L, downstream recovery 50-75%), long approval timelines (3-5 years per ingredient per region), cost pressure (target bulk price $80-120/kg by 2030), and supply-chain concentration (Europe + Japan + China incumbents) still constrain faster scale-up. Company reporting also notes that intensified competition and rising costs (raw materials: glucose, lactose; downstream: chromatography resins, membranes, energy) have already affected project economics, so 3‘-SL looks more like a high-value, tightly regulated, stepwise-expansion ingredient than a mass-market commodity.

Technical Classification & Product Segmentation

The 3‘-Sialyllactose (3‘-SL) market is segmented as below:

Segment by Production Technology

• Microbial Fermentation – Engineered microorganisms (E. coli, yeast (Pichia pastoris), Bacillus subtilis) produce 3‘-SL directly (intracellular or extracellular). Higher titer (60-120 g/L commercial), lower cost (target $80-120/kg). Dominant route (80-85% of production). Novonesis, Inbiose (dsm-firmenich), DSM, Kyowa Hakko (also enzymatic synthesis available), Zhuhai Langjian, Shanghai HuicH.
• Enzymatic Synthesis – Sialyltransferase (ST) or trans-sialidase catalyzes transfer of sialic acid from CMP-sialic acid (or donor substrate) to lactose. Requires CMP-Neu5Ac regeneration system (multi-enzyme). Higher purity (>99% possible), lower byproduct, higher cost (>$300/kg). Niche (10-15%). Kyowa Hakko Bio (enzymatic route optional), GeneChem, Elicityl.

Segment by End-Use Application

• Infant Formula – Stage 1 (0-6 months), Stage 2 (6-12 months), follow-on formula, specialty formula (preterm, low birth weight). Largest segment (70-75% of demand). Requires >98% purity, regulatory approval.
• Food – Functional foods (yogurt, dairy drinks, cereal bars), dietary supplements (capsules, powders, gummies, liquids), medical foods (enteral nutrition). 15-20%.
• Others – Cosmeceuticals (skin health, anti-aging), veterinary (pet probiotics), research reagents. 5-10%.

Key Players & Competitive Landscape

• Novonesis (Denmark) – Global leader. 3‘-SL via fermentation. FDA GRAS, EFSA Novel Food, China NHC approved. Supplies major infant formula brands (Nestlé, Danone, Abbott, Reckitt). Cost competitive.
• Inbiose (dsm-firmenich) (Belgium/Netherlands) – 3‘-SL via fermentation. EFSA Novel Food, FDA GRAS. European leader. Part of dsm-firmenich HMO portfolio.
• DSM (Glycom A/S) (Netherlands/Denmark) – 3‘-SL via fermentation. Acquired by dsm-firmenich (2021). European pioneer.
• Kyowa Hakko Bio (Japan) – 3‘-SL via enzymatic synthesis (sialyltransferase) and fermentation (since 2022). Thailand facility (2022). FDA GRAS (2023), EU Novel Food (2024). Asian supply.
• GeneChem Inc. – South Korean biotech. Enzymatic synthesis. Niche.
• Elicityl (France) – Research scale (mg to grams). Not industrial.
• Zhuhai Langjian Biotechnology (China) – Chinese 3‘-SL manufacturer via fermentation. Received China NHC approval (2026, 3‘-SL sodium salt for infant formula). Domestic supply.
• Shanghai HuicH Biotech (China) – Chinese 3‘-SL R&D, pilot scale. Emerging.

Recent Industry Developments (Last 6 Months – March to September 2026)

• May 2026: China National Health Commission (NHC) approved 3‘-sialyllactose (3‘-SL) sodium salt as novel food ingredient for infant formula (effective May 2026). Permitted up to 200 mg/L (reconstituted formula) for 0-12 months. Chinese domestic manufacturers (Zhuhai Langjian, Shanghai HuicH) first to market domestic 3‘-SL, reducing reliance on Novonesis, Inbiose, DSM, Kyowa Hakko. China is largest infant formula market globally (40-45% share). Domestic 3‘-SL expected to reduce formula production cost by 15-20% vs imported 3‘-SL (tariffs, shipping). Applicable to Chinese brands (Feihe, Yili, Mengniu, Junlebao, Beingmate, Synutra, Ausnutria, H&H Group, Biostime).
• June 2026: Kyowa Hakko Bio (Thailand facility) expanded 3‘-SL production capacity (new 50,000L fermenters, additional downstream purification modules). Targets Chinese infant formula market (NHC approval for 3‘-SL domestic brands). Logistics advantages (Thailand proximity to China, ASEAN trade agreements, lower shipping cost, reduced tariffs). Kyowa claims enzymatic 3‘-SL has superiority (higher purity, lower endotoxin, no organic solvent residues, no genetic modification). Clinical trials ongoing (gut microbiome, immune outcomes).
• Technical challenge identified by QYResearch field surveys (August 2026): 3‘-SL stability in liquid infant formula (sterilization conditions: UHT (ultra-high temperature) 135-150°C, 2-5 seconds; retort 121°C, 10-20 minutes) degrades sialic acid (Neu5Ac) via thermal hydrolysis. Field data from 25 infant formula stability studies (2023-2026):
  • 3‘-SL degradation rate: 15-25% loss after UHT (sterilization), additional 5-10% loss during shelf life (12-24 months, ambient)
  • 6‘-SL more stable (30-50% less degradation) (different linkage)
  • Mitigation: spray-dry infant formula (powder) instead of liquid ready-to-feed (RTF) → minimal degradation (water activity low). RTF liquid formula requires overage (add 20-30% excess 3‘-SL to compensate for sterilization loss, adds cost). Regulatory specification: label claim must be met at end of shelf life (complicated).

Industry Layering: 3‘-SL Production Technology Comparison

Exclusive Observation: “3‘-SL as Bifidobacterium longum subsp. infantis Prebiotic (Synbiotic Pairing)”
In a proprietary QYSearch analysis of 30 human milk microbiome studies (2025-2026), 3‘-SL exhibits selective growth promotion for Bifidobacterium longum subsp. infantis (B. infantis) expressing α2,3-sialidase (clusters of regularly interspaced short palindromic repeats (CRISPR) cluster). Infant formula manufacturers (Evolve Biosystems, Nestlé, Danone, Abbott, Reckitt) combining 3‘-SL + B. infantis probiotic (synbiotic) to simulate breastfed gut microbiome. Clinical trials ongoing (US, Europe, China). Potential premium product development, higher price point. Regulatory pathway: synbiotic requires both GRAS (3‘-SL) and probiotic safety approval. B. infantis strain Evivo (Evolve) commercially available as dietary supplement (not infant formula ingredient yet). FDA infant formula guidance pending.

Conclusion & Outlook
The 3‘-sialyllactose (3‘-SL) market is positioned for very high growth (17.1% CAGR 2026-2032), driven by China NHC approval (2026) enabling domestic infant formula use, established regulatory clearances in EU (Novel Food) and US (FDA GRAS), and premium infant formula demand for human milk-identical oligosaccharides. Infant formula dominates (>70% demand), microbial fermentation dominant production route (80-85%), enzymatic synthesis niche (higher purity, higher cost). Europe (Novonesis, Inbiose/dsm-firmenich, DSM) and Japan (Kyowa Hakko Bio) incumbents; China (Zhuhai Langjian, Shanghai HuicH) fastest-growing domestic supply. The real competitive battleground is no longer only capacity, but also fermentation manufacturing (titer, yield, purity, downstream recovery), purity control (>98% infant formula grade), cross-border registration (China NHC for 3‘-SL sodium salt completed in 2026; 6‘-SL pending; Japan FOSHU under review; Korea MFDS; India FSSAI), and supply reliability (batch-to-batch consistency, contamination control). 3‘-SL looks like a high-value, tightly regulated, stepwise-expansion ingredient (new isomers (6‘-SL), new applications (adult gut health, immune supplements, functional beverages), new geographies (Southeast Asia, India, Middle East, Latin America, Africa)) rather than a mass-market commodity. Manufacturers investing in regulatory clearances (expand approved use levels, categories, geographies), production cost reduction (higher titer, lower purification cost, process intensification, continuous manufacturing), and synbiotic combinations (3‘-SL + B. infantis probiotic) will lead the 3‘-SL market for infant formula, functional foods, and emerging medical nutrition applications.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:

QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp